Maximo F. Nougues - 18 Feb 2026 Form 4 Insider Report for PUMA BIOTECHNOLOGY, INC. (PBYI)

Role
Chief Financial Officer
Signature
/s/ Gordon Esplin as attorney-in-fact for Maximo F. Nougues
Issuer symbol
PBYI
Transactions as of
18 Feb 2026
Net transactions value
$0
Form type
4
Filing time
20 Feb 2026, 20:28:04 UTC
Previous filing
08 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
NOUGUES MAXIMO F Chief Financial Officer C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BLVD., SUITE 1700, LOS ANGELES /s/ Gordon Esplin as attorney-in-fact for Maximo F. Nougues 20 Feb 2026 0001758507

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PBYI Common Stock Award $0 +46,739 +24% $0.000000 240,023 18 Feb 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PBYI Stock Option (Right to Buy) Award $0 +66,541 $0.000000 66,541 18 Feb 2026 Common Stock 66,541 $6.68 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents Restricted Stock Units ("RSUs") that shall vest with respect to one-fourth (1/4th) of the RSUs on each of July 1, 2026, January 1, 2027, July 1, 2027 and January 1, 2028, subject to the Reporting Person's continued service with the Company through the applicable vesting date.
F2 Options shall vest and become exercisable with respect to one-fourth (1/4th) of the shares subject thereto on each of July 1, 2026, January 1, 2027, July 1, 2027 and January 1, 2028, subject to the Reporting Person's continued service with the Company through the applicable vesting date.